Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Century Therapeutics (IPSC) EPS (Basic) (2022 - 2025)

Historic EPS (Basic) for Century Therapeutics (IPSC) over the last 4 years, with Q3 2025 value amounting to -$0.4.

  • Century Therapeutics' EPS (Basic) fell 810.81% to -$0.4 in Q3 2025 from the same period last year, while for Sep 2025 it was -$0.32, marking a year-over-year increase of 8270.27%. This contributed to the annual value of -$1.61 for FY2024, which is 3003.25% up from last year.
  • Latest data reveals that Century Therapeutics reported EPS (Basic) of -$0.4 as of Q3 2025, which was down 810.81% from -$0.38 recorded in Q2 2025.
  • Century Therapeutics' 5-year EPS (Basic) high stood at $0.89 for Q1 2025, and its period low was -$0.66 during Q1 2022.
  • Its 4-year average for EPS (Basic) is -$0.41, with a median of -$0.53 in 2022.
  • Per our database at Business Quant, Century Therapeutics' EPS (Basic) plummeted by 1818.18% in 2023 and then surged by 29778.07% in 2025.
  • Quarter analysis of 4 years shows Century Therapeutics' EPS (Basic) stood at -$0.55 in 2022, then dropped by 18.18% to -$0.65 in 2023, then grew by 29.44% to -$0.46 in 2024, then grew by 12.79% to -$0.4 in 2025.
  • Its last three reported values are -$0.4 in Q3 2025, -$0.38 for Q2 2025, and $0.89 during Q1 2025.